Josep M. Piulats
About
Josep M. Piulats is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Josep M. Piulats has authored 162 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Oncology, 71 papers in Pulmonary and Respiratory Medicine and 38 papers in Molecular Biology. Recurrent topics in Josep M. Piulats's work include Prostate Cancer Treatment and Research (60 papers), Cancer Immunotherapy and Biomarkers (47 papers) and Ocular Oncology and Treatments (37 papers). Josep M. Piulats is often cited by papers focused on Prostate Cancer Treatment and Research (60 papers), Cancer Immunotherapy and Biomarkers (47 papers) and Ocular Oncology and Treatments (37 papers). Josep M. Piulats collaborates with scholars based in Spain, United States and United Kingdom. Josep M. Piulats's co-authors include Xavier Matías‐Guiu, Rebeca Sanz‐Pamplona, August Vidal, Sandra García‐Mulero, Antonio Rullan, J. Maria Caminal Mitjana, Marta Gil-Martín, Rodrigo Dienstmann, David Tamborero and Núria López-Bigas and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.
In The Last Decade
Josep M. Piulats
160 papers receiving 3.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Josep M. Piulats Spain | 30 | 1.5k | 1.1k | 894 | 847 | 733 | 162 | 3.2k | ||
| Alexander N. Shoushtari United States | 34 | 3.3k 2.2× | 1.4k 1.3× | 1.6k 1.8× | 833 1.0× | 997 1.4× | 167 | 4.7k | ||
| Thierry Lesimple France | 32 | 2.0k 1.3× | 1.2k 1.1× | 416 0.5× | 1.0k 1.2× | 85 0.1× | 139 | 3.3k | ||
| Maresa Altomonte Italy | 36 | 2.1k 1.4× | 1.6k 1.5× | 1.7k 1.9× | 856 1.0× | 97 0.1× | 95 | 4.4k | ||
| Lewis C. Strauss United States | 27 | 1.2k 0.8× | 955 0.9× | 803 0.9× | 540 0.6× | 128 0.2× | 64 | 3.8k | ||
| Allan Topham United States | 17 | 1.2k 0.8× | 700 0.6× | 342 0.4× | 367 0.4× | 1.3k 1.8× | 24 | 2.6k | ||
| Hee Eun Lee South Korea | 29 | 1.3k 0.9× | 1.0k 0.9× | 142 0.2× | 707 0.8× | 145 0.2× | 86 | 2.7k | ||
| Friedrich Prall Germany | 28 | 1.5k 1.0× | 479 0.4× | 274 0.3× | 439 0.5× | 80 0.1× | 80 | 2.4k | ||
| Stanley W. McCarthy Australia | 35 | 2.5k 1.7× | 1.6k 1.4× | 628 0.7× | 453 0.5× | 144 0.2× | 73 | 3.7k | ||
| Zeynep Eroglu United States | 26 | 2.8k 1.9× | 1.2k 1.1× | 1.1k 1.2× | 557 0.7× | 230 0.3× | 124 | 3.7k | ||
| Adi Diab United States | 38 | 4.0k 2.7× | 779 0.7× | 2.0k 2.2× | 923 1.1× | 180 0.2× | 194 | 5.2k |
Countries citing papers authored by Josep M. Piulats
Since
Specialization
Citations
This map shows the geographic impact of Josep M. Piulats's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josep M. Piulats with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josep M. Piulats more than expected).
Fields of papers citing papers by Josep M. Piulats
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Josep M. Piulats. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josep M. Piulats. The network helps show where Josep M. Piulats may publish in the future.
Co-authorship network of co-authors of Josep M. Piulats
This figure shows the co-authorship network connecting the top 25 collaborators of Josep M. Piulats. A scholar is included among the top collaborators of Josep M. Piulats based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josep M. Piulats. Josep M. Piulats is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bryce, Alan H., Ray McDermott, Josep M. Piulats, et al.. (2025). Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.. Journal of Clinical Oncology. 43(5_suppl). 155–155.
2.
Agarwal, Neeraj, Daniel Castellano, Teresa Alonso‐Gordoa, et al.. (2024). A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1. Clinical Cancer Research. 30(11). 2377–2383.
3.
Mehra, Niven, Jens Voortman, David R. Wise, et al.. (2024). Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). TPS2672–TPS2672.
4.
Jahangir, Chowdhury Arif, Sandra García‐Mulero, Arman Rahman, et al.. (2023). 1,4-dihydroxy quininib modulates the secretome of uveal melanoma tumour explants and a marker of oxidative phosphorylation in a metastatic xenograft model. Frontiers in Medicine. 9. 1036322–1036322.
5.
García‐Mulero, Sandra, Marco Punta, Stefano Lise, et al.. (2023). Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients. OncoImmunology. 12(1). 2261278–2261278.
6.
Smith, Matthew R., Nobuaki Matsubara, Rana R. McKay, et al.. (2023). CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology. 41(6_suppl). TPS289–TPS289.
7.
Castillo, J.J. Soto, Rafael Moreno, Carles Codony, et al.. (2023). SWI/SNF Complex Alterations in Tumors with Rhabdoid Features: Novel Therapeutic Approaches and Opportunities for Adoptive Cell Therapy. International Journal of Molecular Sciences. 24(13). 11143–11143.
8.
Poulard, Coralie, Montserrat Abella, Rosa Antón, et al.. (2023). A hotspot for posttranslational modifications on the androgen receptor dimer interface drives pathology and anti-androgen resistance. Science Advances. 9(11). eade2175–eade2175.
9.
Piulats, Josep M., et al.. (2023). Detection of the Uveal Melanoma-Associated Mutation GNAQ Q209P from Liquid Biopsy Using CRISPR/Cas12a Technology. Analytical Chemistry. 95(45). 16692–16700.
10.
García‐Mulero, Sandra, et al.. (2022). Facts and Hopes in Immunotherapy of Endometrial Cancer. Clinical Cancer Research. 28(22). 4849–4860.
11.
Palomero, Jara, Ana Vivancos, Carlos E. de Andrea, et al.. (2022). Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer.. Journal for ImmunoTherapy of Cancer. 10(12). e005443–e005443.
12.
Benavente, Yolanda, Jordi Ponce, Joan Brunet, et al.. (2020). Sensitivity of cervico‐vaginal cytology in endometrial carcinoma: A systematic review and meta‐analysis. Cancer Cytopathology. 128(11). 792–802.
13.
Carles, Joan, Teresa Alonso, B. Mellado González, et al.. (2020). 639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide. Annals of Oncology. 31. S525–S526.
14.
Piperno‐Neumann, Sophie, Josep M. Piulats, Matthias Goebeler, et al.. (2019). Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. Cancers. 11(6). 817–817.
15.
Barceló, Carla, Pol Sisó, Óscar Maiques, et al.. (2019). T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma. Journal of Investigative Dermatology. 140(6). 1253–1265.
16.
García, Margarita, Rafael Moreno, Marta Gil-Martín, et al.. (2018). A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. Human Gene Therapy. 30(3). 352–364.
17.
Tamborero, David, Carlota Rubio-Pérez, Ferran Muiños, et al.. (2018). A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. Clinical Cancer Research. 24(15). 3717–3728.
18.
Piulats, Josep M., Cristina Gutiérrez, Luís Arias, et al.. (2017). Prognostic Factors and Decision Tree for Long-Term Survival in Metastatic Uveal Melanoma. Cancer Research and Treatment. 50(4). 1130–1139.
19.
Algazi, Alain P., Katy K. Tsai, Alexander N. Shoushtari, et al.. (2016). Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies. Cancer. 122(21). 3344–3353.
20.
Piulats, Josep M., Xavier García del Muro, August Vidal, et al.. (2009). Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors. Clinical Cancer Research. 15(10). 3384–3395.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alexander N. Shoushtari Breakdown of academic impact, for papers by Thierry Lesimple Breakdown of academic impact, for papers by Maresa Altomonte Breakdown of academic impact, for papers by Lewis C. Strauss Breakdown of academic impact, for papers by Allan Topham Breakdown of academic impact, for papers by Hee Eun Lee Breakdown of academic impact, for papers by Friedrich Prall Breakdown of academic impact, for papers by Stanley W. McCarthy Breakdown of academic impact, for papers by Zeynep Eroglu Breakdown of academic impact, for papers by Adi Diab